Mandate

Vinge advises AstraZeneca

January 30, 2013

Vinge has advised AstraZeneca in connection with the sale of its research facility in Södertälje to Acturum, a group formed by FAM, the Wallenber foundations’ management company, and PEAB. The transaction covers, among other things, real estate, laboratories, research projects and a significant number of laboratory equipment and is intended to create conditions for future research and enterprise within the entire filed of life science.

Vinge’s team consisted of responsible partner Malin Ohlin and associate Kristina Ekberg and also included partner Patrick Forslund and associates Daniel Unger, Johan Cederblad, Nazli Zia, Peter Alstergren, Claes Henriksson and project assistant Sara Andersson.

Related

Vinge has advised Orexo in connection with its rights issue

Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB.
October 08, 2026

Vinge has advised Folksam Group in connection with two investments in infrastructure funds

Vinge has advised Folksam Group in connection with two investments totalling SEK 7.2 billion in infrastructure funds managed by Copenhagen Infrastructure Partners and Arjun Infrastructure Partners, respectively.
October 08, 2026